Rationale for combined therapies in severe-to-critical COVID-19 patients.
Gonzaga A, Andreu E, Hernández-Blasco LM, Meseguer R, Al-Akioui-Sanz K, Soria-Juan B, Sanjuan-Gimenez JC, Ferreras C, Tejedo JR, Lopez-Lluch G, Goterris R, Maciá L, Sempere-Ortells JM, Hmadcha A, Borobia A, Vicario JL, Bonora A, Aguilar-Gallardo C, Poveda JL, Arbona C, Alenda C, Tarín F, Marco FM, Merino E, Jaime F, Ferreres J, Figueira JC, Cañada-Illana C, Querol S, Guerreiro M, Eguizabal C, Martín-Quirós A, Robles-Marhuenda Á, Pérez-Martínez A, Solano C, Soria B.
Gonzaga A, et al. Among authors: poveda jl.
Front Immunol. 2023 Sep 11;14:1232472. doi: 10.3389/fimmu.2023.1232472. eCollection 2023.
Front Immunol. 2023.
PMID: 37767093
Free PMC article.
Review.